Mutual expertise drives innovations to address supply issues for vaccines for outbreak pathogens NEW YORK — MARCH 5, 2020 — IAVI, a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, and Batavia Biosciences, a contract development and manufacturing organization focused on delivering sustainable manufacturing solutions in the field of infectious disease…
Ten years ago, Christopher Yallop and Menzo Havenga incorporated Batavia Biosciences at the chamber of commerce in the Netherlands. The company started operations on January 1, 2010 at that time with 7 employees (our “magnificent seven”). Today, we are a 100 people strong with operations in the US, Asia, and the Netherlands and we are…
We are proud to announce that our CEO, Menzo Havenga, has won the CEO Today Healthcare Award 2019. Menzo is praised for his leading role in the biopharmaceutical medicines development sector and his strive to ensure biopharmaceuticals are affordable and available for all in need. In an interview with CEO Today Magazine, Menzo Havenga commented:…
Leiden, the Netherlands, Nov 12, 2019 – We are proud to announce that we have partnered with IAVI under an award they have received from the US Defense Threat Reduction Agency (DTRA) to develop a VSV-based vaccine against Marburg virus. (Link to IAVI press release) This is the second collaboration between Batavia and IAVI on VSV…
Batavia Biosciences has once again been selected as National Winner in the award category ‘Innovation’ in The European Business Awards, Europe’s largest business competition. The award to Batavia was granted by a panel of independent judges including senior business leaders, politicians and academics during a fierce competition involving 98 Dutch nominated companies. Menzo Havenga, CEO…
Leiden, the Netherlands, Sep 16, 2019 – Today, Batavia Biosciences announces it received a grant of $6.5 million from the Bill & Melinda Gates Foundation to develop a manufacturing process for a novel oral vaccine against polio virus type 2 strain (nOPV2) to help protect children worldwide from future polio outbreaks. In a collaboration with…
Leiden, 3 September 2019 – Today, Batavia Biosciences announced that the company has signed a license agreement to utilize Horizon Discovery’s GS knockout CHO K1 cell line expression system for the development of high yield antibody-expressing cell lines. Initially, Batavia will deploy the system for production of a potent Zika virus neutralizing antibody, working in…
Leiden, 4 Jul 2019 – Today, Batavia Biosciences announces it received a follow-up grant of $2.2 million from PATH – a global organization dedicated to health equity – to develop and manufacture novel oral poliovirus vaccines (nOPV). The project, which is funded by the Bill & Melinda Gates Foundation, aims to protect children worldwide from…
Grant from the Bill & Melinda Gates Foundation will support Univercells and partner Batavia Biosciences to develop a cost-effective manufacturing process and proceed towards the successful commercialization of measles and rubella vaccines. BRUSSELS, BELGIUM – JUNE, 13 2019 Univercells announced today that it has been awarded a $14.3 million grant by the Bill & Melinda Gates…
Leiden, the Netherlands, May 14, 2019 – Batavia Biosciences announced today that it will work together in a consortium including the European Vaccine Initiative and Stanford University, icddr,b, and headed by the University of Tokyo, to develop an epidemic preparedness vaccine against the Nipah virus. For this purpose, the University of Tokyo received a $31…